Feedback / Questions
vibostolimab/pembrolizumab (MK-7684A) - Merck (MSD)
sacituzumab tirumotecan (MK-2870) - Merck (MSD)
tagitanlimab (HBM9167) - Harbour BioMed
https://www.businesswire.com/news/home/20240515813046/en/Merck-to-Present-New-Data-at-2024-ASCO-Annual-Meeting-Demonstrating-Advancements-in-Novel-Oncology-Treatment-Approaches-Across-Broad-Portfolio-and-Diverse-Pipeline
May 15, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next